Zhi‐Bin Wang

Zhi‐Bin Wang

Auto-generated profile, based on publicly available information

Zhi‐Bin Wang

Department of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital Central South University Changsha P.R. China

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 February 2024 in Ultrasonics Sonochemistry
Verified
Journal Article
Open access
SJShuang Jiang
Shuang Jiang
QWQianbo Wang
Qianbo Wang
ZWZhibin Wang
Zhibin Wang
GBGilwa Borjigin
Gilwa Borjigin
JSJiahui Sun
Jiahui Sun
CYChunjuan Yang
Chunjuan Yang
Fritillaria ussuriensis Maxim. (F.M.) has been widely used in both food and medication for more than 2000 years. In order to achieve its comprehensive utilization and investigate the structural characterization and biology activity, response surface methodology (RSM) was used to optimize the ultrasound-assisted extraction conditions of F.M. polysaccharides. The optimal extraction conditions were ultrasonic power of 174.2 W, ratio of liquid to material of 40.7 mL/g and ultrasonic time of 82.0 min. In addition, a neutral polysaccharide F-1 was obtained, and its structure characterization, antioxidant and immunological activity were evaluated. The structural properties of the polysaccharide were characterized by UV, IR, GC-MS, NMR and AFM. Monosaccharide composition of F-1 (MW 18.11 kDa) was rhamnose, arabinose, glucosamine hydrochloride, galactose, and glucose which under the ratio of 0.9: 3.8: 0.2: 2.9: 92.2. The fractions of F-1 were mainly linked by → 6)-α-D-Glcp-(1 → with branch chain α-D-Glcp-(1 → 4)-α-D-Glcp-(1 → and 4,6)-α-D-Glcp-(1 → residues. Moreover, F-1 has a significant scavenging activity, which can clear hydroxyl radicals, superoxide anion, DPPH and ABTS. In addition, the immunological activity showed that F-1 had an effect on macrophage phagocytic activity. And it can increase the release of inflammatory factors including TNF-α, IL-1β and IL-6. F-1 is a novel polysaccharide with significant activity in antioxidant and immunological activity, which has great potential for antioxidant and immunizer in food, pharmaceutical and cosmetic industries. The study can provide a methodological basis for polysaccharide research and theoretical basis for the industrialized production and practical application.

17 May 2019 in CNS Neuroscience & Therapeutics
Verified
Journal Article
Open access
PDF file
YGYuan‐Feng Gao
Yuan‐Feng Gao
JLJun‐Yan Liu
Jun‐Yan Liu
XMXiao‐Yuan Mao
Xiao‐Yuan Mao
ZHZheng‐Wen He
Zheng‐Wen He
TZTao Zhu
Tao Zhu
ZLZhao-Qian Liu
Zhao-Qian Liu
Aims: Altered activities of long noncoding RNAs (lncRNAs) have been associated with cancer development, and lncRNA FOXD1‐AS1 (FOXD1‐AS1) is the antisense transcript of the gene encoding for FOXD1, known for its role as an oncogene in several tumor types including glioma. However, the role of FOXD1‐AS1 in the differentiation and progression of glioma is not well known.Methods: Expression profile chip and qPCR were used to screen and identify FOXD1‐AS1. Glioma cells were transfected with siRNA or eukaryotic expression vector to observe FOXD1‐AS1 function in vitro and in vivo. Dual luciferase reporter gene analysis, Western blot, and ChIRP‐MS were used to detect microRNAs and protein that combine with FOXD1‐AS1.Results: FOXD1‐AS1 was upregulated and directly correlated with the glioma grade, and it was localized in both the nucleus and the cytoplasm of the glioma cell. FOXD1‐AS1 silencing caused tumor suppressive effects via inhibiting cell proliferation, migration, and apoptosis, while FOXD1‐AS1 overexpression resulted in opposite effects. Additionally, in vivo experiments showed that FOXD1‐AS1 knockdown reduced tumor volume and weight. More importantly, mechanical studies revealed that FOXD1‐AS1 targeted both miR339‐5p and miR342‐3p (miR339/342). Furthermore, protein eukaryotic translation initiation factor 5 subunit A (eIF5a) resulted a direct target of FOXD1‐AS1.Conclusions: These data indicated that FOXD1‐AS1, a miR339/342 target, affected biological processes via protein eIF5a; thus, it might be considered as a new therapeutic target for glioblastoma.

15 August 2024 in CNS Neuroscience & Therapeutics
Verified
Journal Article
Open access
ZWZhi‐Bin Wang
Zhi‐Bin Wang
JLJun‐Yan Liu
Jun‐Yan Liu
SJShi‐Long Jiang
Shi‐Long Jiang
WZWei Zhuo
Wei Zhuo
PXPan Xie
Pan Xie
ZLZhao-Qian Liu
Zhao-Qian Liu
Background: Epilepsy is a widespread central nervous system disorder with an estimated 50 million people affected globally. It is characterized by a bimodal incidence peak among infants and the elderly and is influenced by a variety of risk factors, including a significant genetic component. Despite the use of anti‐epileptic drugs (AEDs), drug‐refractory epilepsy develops in about one‐third of patients, highlighting the need for alternative therapeutic approaches.Aims: The primary aim of this study was to evaluate the neuroprotective effects of troglitazone (TGZ) in epilepsy and to explore the potential mechanisms underlying its action.Methods: We employed both in vitro and in vivo models to assess TGZ's effects. The in vitro model involved glutamate‐induced toxicity in HT22 mouse hippocampal neurons, while the in vivo model used kainic acid (KA) to induce epilepsy in mice. A range of methods, including Hoechst/PI staining, CCK‐8 assay, flow cytometry, RT‐PCR analysis, Nissl staining, scanning electron microscopy, and RNA sequencing, were utilized to assess various parameters such as cellular damage, viability, lipid‐ROS levels, mitochondrial membrane potential, mRNA expression, seizure grade, and mitochondrial morphology.Results: Our results indicate that TGZ, at doses of 5 or 20 mg/kg/day, significantly reduces KA‐induced seizures and neuronal damage in mice by inhibiting the process of ferroptosis. Furthermore, TGZ was found to prevent changes in mitochondrial morphology. In the glutamate‐induced HT22 cell damage model, 2.5 μM TGZ effectively suppressed neuronal ferroptosis, as shown by a reduction in lipid‐ROS accumulation, a decrease in mitochondrial membrane potential, and an increase in PTGS2 expression. The anti‐ferroptotic effect of TGZ was confirmed in an erastin‐induced HT22 cell damage model as well. Additionally, TGZ reversed the upregulation of Plaur expression in HT22 cells treated with glutamate or erastin. The downregulation of Plaur expression was found to alleviate seizures and reduce neuronal damage in the mouse hippocampus.Conclusion: This study demonstrates that troglitazone has significant therapeutic potential in the treatment of epilepsy by reducing epileptic seizures and the associated brain damage through the inhibition of neuronal ferroptosis. The downregulation of Plaur expression plays a crucial role in TGZ's anti‐ferroptotic effect, offering a promising avenue for the development of new epilepsy treatments.

27 August 2021 in Frontiers in Pharmacology
Verified
Journal Article
Open access
SJShi-Long Jiang
Shi-Long Jiang
ZWZhi-Bin Wang
Zhi-Bin Wang
TZTao Zhu
Tao Zhu
TJTing Jiang
Ting Jiang
JFJiang-Feng Fei
Jiang-Feng Fei
ZLZhao-Qian Liu
Zhao-Qian Liu
Vemurafenib, a BRAF V600E inhibitor, provides therapeutic benefits for patients with melanoma, but the frequent emergence of drug resistance remains a challenge. An understanding of the mechanisms underlying vemurafenib resistance may generate novel therapeutic strategies for patients with melanoma. Here, we showed that eIF3a, a translational regulatory protein, was an important mediator involved in vemurafenib resistance. eIF3a was expressed at significantly lower levels in vemurafenib-resistant A375 melanoma cells (A375R) than in parental A375 cells. Overexpression of eIF3a enhanced the sensitivity to BRAF inhibitors by reducing p-ERK levels. Furthermore, eIF3a controlled ERK activity by regulating the expression of the phosphatase PPP2R1B via a translation mechanism, thus determining the sensitivity of melanoma cells to vemurafenib. In addition, a positive correlation between eIF3a and PPP2R1B expression was also observed in tumor samples from the Human Protein Atlas and TCGA databases. In conclusion, our studies reveal a previously unknown molecular mechanism of BRAF inhibitor resistance, which may provide a new strategy for predicting vemurafenib responses in clinical treatment.

1 October 2014 in CNS Neuroscience & Therapeutics
Verified
Journal Article
Open access
PDF file
YZYing Zhang
Ying Zhang
JQJian Qu
Jian Qu
CMChen‐Xue Mao
Chen‐Xue Mao
ZWZhi‐Bin Wang
Zhi‐Bin Wang
Xiao-Yuan MaoXiao-Yuan Mao
Xiao-Yuan Mao
ZLZhao-Qian Liu
Zhao-Qian Liu